Lördag 18 Oktober | 18:56:06 Europe / Stockholm

Kalender

Est. tid*
2025-08-28 - Kvartalsrapport 2025-Q2
2025-04-07 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 - Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden från onkologi till neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.
2025-10-07 16:30:00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies Plc MANAGERS’ TRANSACTIONS October 7, 2025 5:30p.m. EEST

Aiforia Technologies Plc has received a notification from Tuomas Tenkanen, Aiforia Technologies Plc's Board member, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation.

Detailed information about the transaction is given here under.

Aiforia Technologies Plc - Managers' Transactions

____________________________________________

Person subject to the notification requirement
Name: TJT Technologies Oy
Position: Chief Executive Officer
(X) Legal person (1): Person discharging managerial responsibilities in issuer
Name: Tuomas Tenkanen
Position: Member of the Board

Issuer: Aiforia Technologies Plc
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 125660/6/12

____________________________________________

Transaction date: 2025-10-06
Venue: DNFI
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 900 Unit price: 2.65 EUR

Aggregated transactions (1):
Volume: 900 Volume weighted average price: 2.65 EUR

____________________________________________

Transaction date: 2025-10-06
Venue: EBLX
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 8,000 Unit price: 2.65 EUR

Aggregated transactions (1):
Volume: 8,000 Volume weighted average price: 2.65 EUR

____________________________________________

Transaction date: 2025-10-06
Venue: POSIT (XPOS)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 10,000 Unit price: 2.65 EUR

Aggregated transactions (1):
Volume: 10,000 Volume weighted average price: 2.65 EUR

 

Further inquiries 
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878 https://investors.aiforia.com/

 

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia  

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com